Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

Sands, B E; Tremaine, W J; Sandborn, W J; Rutgeerts, P J; Hanauer, S B; Mayer, L; Targan, S R; Podolsky, D K

Sands, B E; Tremaine, W J; Sandborn, W J; Rutgeerts, P J; Hanauer, S B; Mayer, L; Targan, S R; Podolsky, D K.

Affiliation

Sands BE; Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston 02114, USA.

Inflamm Bowel Dis ; 7(2): 83-8, 2001 May.

Article in En | MEDLINE | ID: mdl-11383595

Subject(s)

Antibodies, Monoclonal/therapeutic use; Colitis, Ulcerative/drug therapy; Gastrointestinal Agents/therapeutic use; Adrenal Cortex Hormones/therapeutic use; Adult; Aged; Anti-Inflammatory Agents/therapeutic use; Antibodies, Monoclonal/adverse effects; Colitis, Ulcerative/blood; Colitis, Ulcerative/surgery; Double-Blind Method; Drug Resistance; Female; Gastrointestinal Agents/adverse effects; Humans; Infliximab; Male; Middle Aged; Pilot Projects; Steroids; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Gastrointestinal Agents / Colitis, Ulcerative / Antibodies, Monoclonal Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Inflamm Bowel Dis Journal subject: GASTROENTEROLOGIA Year: 2001 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links